Monopar Therapeutics Provides Update On MNPR-101-Zr Radiopharma Clinical Trial-8K
Portfolio Pulse from Benzinga Newsdesk
Monopar Therapeutics announced Professor Rodney Hicks as the lead investigator for the Phase 1 dosimetry clinical trial of MNPR-101-Zr in advanced cancer patients. The trial will take place at the Melbourne Theranostic Innovation Centre using the Siemens Biograph Vision Quadra PET/CT scanner.
February 27, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Monopar Therapeutics advances its MNPR-101-Zr clinical trial for cancer with a renowned investigator and cutting-edge imaging technology.
The announcement of a leading investigator and the use of advanced imaging technology for Monopar's clinical trial could positively influence investor perception, potentially leading to an increase in stock price due to heightened expectations for successful trial outcomes.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100